2022 American Transplant Congress
Impact of Glecaprevir/Pibrentasvir on Tacrolimus Concentration in Solid Organ Transplant Recipients with or without Triazole Antifungal Therapy
*Purpose: Provide guidance on tacrolimus (TAC) dose adjustments during glecaprevir/pibrentasvir (GLE/PIB) initiation and discontinuation in patients on triazole antifungals by comparing changes in TAC concentration-dose…2022 American Transplant Congress
Long-Term Follow Up of Solid Organ Transplantation Using Hepatitis C Virus Positive Donor for Hepatitis C Virus Negative Recipients
*Purpose: To determine the effects of transplanting an HCV + solid organ to an uninfected patient who is on the transplant waiting list. Outcomes include…2022 American Transplant Congress
The Oncological Influences of Pre- and Post-Transplant Sustained Viral Response in Liver Transplant for Hepatocellular Carcinoma
*Purpose: Chronic hepatitis C infection (HCV) is one of the most common causes of hepatocellular carcinoma. After emerging direct-acting agents (DAA), the success rate of…2022 American Transplant Congress
Transplantation of Hepatitis C Viremic Donor Organs to Hepatitis C Nonviremic Recipients: A Retrospective Review
*Purpose: The advent of combination direct-acting antiviral (DAA) agents has improved the ability to treat hepatitis C virus (HCV) infections. As a result, utilization of…2022 American Transplant Congress
Hepatitis C (HCV) Positive Recipients and/or Donors in Pancreas Transplantation – A Registry Analysis
SUNY Downstate Medical Center, Brooklyn, NY
*Purpose: Pancreas transplantation (PT) is the best long-term option for patients with labile diabetes and end-stage-renal disease. The mortality on the waitlist is high; patients…2022 American Transplant Congress
Hepatitis C Positive Kidney Transplant Into Hepatitis C Negative Recipients
*Purpose: Kidney transplantation is the treatment of choice in end stage renal disease (ESRD). In 2018, 5% to 8% of eligible adults died while on…2022 American Transplant Congress
Ultra-Short Duration Prophylaxis for Hepatitis C Donor Positive to Recipient Negative Simultaneous Kidney/Pancreas Transplants
Virginia Commonwealth University, Richmond, VA
*Purpose: Recent trials have successfully utilized a strategy of hepatitis C virus (HCV) D+ [Donor nucleic acid test (NAT) positive]/R- (Recipient NAT negative) kidney and/or…2022 American Transplant Congress
Use of Kidneys from Hepatitis C Nat Positive Donors for Uninfected Recipients: Early Results from a Rural Appalachian Kidney Transplant Program
*Purpose: Increasing mismatch between kidneys available for transplant and the number of patients on the transplant wait list has led to research into novel sources…2022 American Transplant Congress
Is Donor Hepatitis C Virus Infection Status Associated with Early Post-Kidney Transplant Failure in the Era of Direct-Acting Antiviral Medications?
*Purpose: To determine the influence of donor hepatitis C virus (HCV) infection status on early kidney transplant (KT) failure in HCV negative recipients in the…2022 American Transplant Congress
Outcomes in Hepatitis C (HCV) Viremic Grafts to HCV Negative Recipients in Heart Transplantation: A Multicenter Study of Differing Treatment Strategies
*Purpose: Using HCV viremic grafts for heart transplantation (HT) improves donor supply and shortens wait times. However, treatment strategies are variable post-transplant. This study aims…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 28
- Next Page »